Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 24, Issue 4, 2006, Pages 688-694

  Yasuda, Hiroyasu ^a   Yamaya, Mutsuo ^a   Nakayama, Katsutoshi ^a   Sasaki, Takahiko ^a   Ebihara, Satoru ^a   Kanda, Akio ^a   Asada, Masanori ^a   Inoue, Daisuke ^a   Suzuki, Tomoko ^a   Okazaki, Tatsuma ^a   Takahashi, Hidenori ^a   Yoshida, Motoki ^a   Kaneta, Tomohiro ^a   Ishizawa, Kota ^a   Yamanda, Shinsuke ^a   Tomita, Naoki ^a   Yamasaki, Miyako ^a   Kikuchi, Akiko ^a   Kubo, Hiroshi ^a   Sasaki, Hidetada ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLYCERYL TRINITRATE; NAVELBINE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VASCULOTROPIN A; VINBLASTINE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; AGED; BLOOD; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NITROGLYCERIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VINBLASTINE;

EID: 33644838950     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.0436     Document Type: Article

References (57)

1. Sutherland RM: Importance of critical metabolites and cellular interactions in the biology of microregions of tumor. Cancer 58:1668-1680, 1986
2. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549, 1955
3. Brown JM: The hypoxic cell: A target for selective cancer therapy - Eighteenth Bruth F. Cain Memorial Award Lecture. Cancer Res 59:5863-5870, 1999
4. Sutherland RM: Cell and environmental interactions in tumor microregions: The multicell spheroid model. Science 240:177-184, 1988
5. Moulder JE, Rockwell S: Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev 5:313-341, 1987
6. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416, 1998
7. Hockel M, Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276, 2001
8. Liang BC: Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 29:149-155, 1996
9. Sanna K, Rofstad EK: Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 58:258-262, 1994
10. Semenza GL, Roth PH, Fang HM, et al: Transcriptional regulation of gene encoding glycolytic enzyme by hypoxia-inducible factor 1. J Biol Chem 269:23757-23763, 1994
11. Wilson RE, Keng PC, Sutherland RM: Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst 81:1235-1240, 1989 [erratum: J Natl Cancer Inst 82:239, 1990]
12. Semenza GL: Targeting HIF-1 for cancer therapy. Nature Rev Cancer 3:721-732, 2003
13. Hofer T, Wenger H, Gassmann M: Oxygen sensing, HIF-1α stabilization and potential therapeutic strategies. Pflugers Arch 443:503-507, 2002
14. Yeo EJ, Chun YS, Cho YS, et al: YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516-525, 2003
15. Pili R, Donehower RC: Is HIF-1α a valid therapeutic target? J Natl Cancer Inst 95:498-499, 2003
16. Matthews NE, Adams MA, Maxwell LR, et al: Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 93:1879-1885, 2001
17. Huang LE, Willmore WG, Gu J, et al: Inhibition of hypoxia- inducible factor 1 activation by carbon monoxide and nitric oxide. J Biol Chem 274:9038-9044, 1999
18. Takabuchi S, Hirota K, Nishi K, et al: The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway. Biochem Biophys Res Commun 324:417-423, 2004
19. Hagen T, Taylor CT, Lam F, et al: Redistribution of intracellular oxygen in hypoxia by nitric oxide: Effect on HIF1alpha. Science 302:1975-1978, 2003
20. Thomas DD, Espey MG, Ridnour LA, et al: Hypoxic inducible factor 1 alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A 101:8894-8899, 2004
21. Jordan BF, Misson P, Demeure R, et al: Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: Monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 48:565-570, 2000
22. Xie K, Huang S, Dong Z, et al: Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 89:421-427, 1997
23. Vamvakas S, Schmidt HHHW: Just say NO to Cancer? J Natl Cancer Inst 89:406-407, 1997
24. Jarry A, Charrier L, Bou-Hannna C, et al: Position in cell cycle controls the sensitivity of colon cancer cells to nitric oxide-dependent programmed cell death. Cancer Res 64:4227-4234, 2004
25. Cook T, Wang Z, Alber S, et al: Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 64:8015-8021, 2004
26. Gallo O, Masini E, Morbidelli L, et al: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90:587-596, 1998
27. Garcia-Cardena G, Folkman J: Is there a role for nitric oxide in tumor angiogenesis? J Natl Cancer Inst 90:560-561, 1998
28. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
29. Hoffman PC, Mauer AM, Vokes EE: Lung cancer. Lancet 355:479-485, 2000
30. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
31. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
32. Edelman MJ, Clark JI, Chansky K, et al: Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10:5022-5026, 2004
33. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
34. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
35. Parker JD, Parker JO: Nitrate therapy for stable angina pectoris. N Engl J Med 338:520-531, 1998
36. Trotti A, Byhardt R, Stetz J, et al: Common toxicity criteria: Version 2.0 - An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13-47, 2000
37. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
38. Machin D, Cambel M, Fayers P, et al: Comparing Two Survival Curves: Sample Size Tables for Clinical Studies (ed 2). Oxford, United Kingdom, Blackwell Science, 1997, pp 174-253
39. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
40. Kanda A, Ebihara S, Takahashi H, et al: Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor. Acta Oncol 42:62-70, 2003
41. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21:3016-3024, 2003
42. Kelley K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
43. Georgoulias V, Ardavanis A, Tsiafaki X, et al: Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 23:2937-2945, 2005
44. Smith IE, O'Brien ME, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1343, 2001
45. Wartenberg M, Ling FC, Muschen M, et al: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor-1 and reactive oxygen species. FASEB J 17:503-505, 2003
46. Koomagi R, Mattern J, Volm M: Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LPR56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res 19:4333-4336, 1999
47. Semenza GL: HIF-1 and mechanism of hypoxia sensing. Curr Opin Cell Biol 13:167-171, 2001
48. Wenger RH, Gassmann M: Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 378:609-616, 1997
49. Bunn HF, Poyton RQ: Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76: 839-885, 1996
50. Shweiki D, Itin A, Softer D, et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992
51. Song CW: Modification of blood flow. In: Molls M, Vaupel P (eds): Blood Perfusion and Microenvironment of Human Tumors: Implications for Clinical Radiooncology. Berlin, Springer-Verlag, 1998, pp 193-207
52. Li LM, Kilbourn RG, Adams J, et al: Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res 51:2531-2535, 1991
53. Pervin S, Singh R, Chaudhuri G: Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): Potential role of cyclin D1. Proc Natl Acad Sci U S A 98:3583-3588, 2001
54. Lowe SW, Ruley HE, Jacks T, et al: P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
55. Safran H, King T, Choy H, et al: p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer 78:1203-1210, 1996
56. Schuler M, Herrmann R, De Greve JL, et al: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J Clin Oncol 19:1750-1758, 2001
57. Raval RR, Lau KW, Tran MG, et al: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25:5675-5686, 2005